Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir K Gupta

Showing results (1-10 of 119) with videos related to

Pageof 12
Sort By:
Annals of Internal Medicine|February 18, 2009
Can the SMART study data be used to assess risk factors for renal disease?Samir K Gupta
The AIDS Reader|August 1, 2009
Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?Samir K Gupta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2005
Tenofovir and changes in renal functionSamir K Gupta
The Lancet. Infectious Diseases|December 3, 2014
Antiretroviral treatment initiationSamir K Gupta
AIDS Patient Care and Stds|February 12, 2008
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting systemSamir K Gupta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 31, 2002
Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophySamir K Gupta, Michael P Dubé
European Journal of Clinical Pharmacology|November 1, 2011
Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patientsSamir K Gupta, Bhavna Kantesaria, Paul Glue
Drug Discoveries & Therapeutics|May 13, 2014
Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosingSamir K Gupta, Bhavna Kantesaria, Paul Glue
Drug Discoveries & Therapeutics|September 28, 2013
Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairmentSamir K Gupta, Bhavna Kantesaria, Paul Glue
Kidney International|September 17, 2008
Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tellKara K Wools-Kaloustian, Samir K Gupta
Pageof 12

Showing results (1-10 of 119) with videos related to

Sort By:
Pageof 12
Annals of Internal Medicine|February 18, 2009
Can the SMART study data be used to assess risk factors for renal disease?Samir K Gupta
The AIDS Reader|August 1, 2009
Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?Samir K Gupta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 20, 2005
Tenofovir and changes in renal functionSamir K Gupta
The Lancet. Infectious Diseases|December 3, 2014
Antiretroviral treatment initiationSamir K Gupta
AIDS Patient Care and Stds|February 12, 2008
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting systemSamir K Gupta
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 31, 2002
Exogenous cushing syndrome mimicking human immunodeficiency virus lipodystrophySamir K Gupta, Michael P Dubé
European Journal of Clinical Pharmacology|November 1, 2011
Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patientsSamir K Gupta, Bhavna Kantesaria, Paul Glue
Drug Discoveries & Therapeutics|May 13, 2014
Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosingSamir K Gupta, Bhavna Kantesaria, Paul Glue
Drug Discoveries & Therapeutics|September 28, 2013
Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairmentSamir K Gupta, Bhavna Kantesaria, Paul Glue
Kidney International|September 17, 2008
Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tellKara K Wools-Kaloustian, Samir K Gupta
Pageof 12